Genmab — Juni 2018
-
-
unfortunately a lot of investors will not know the difference between solids, MM and all that ; they see a failure, they already had a 25% drop, and they flee. On top of that, they see in the newspaper that CART is going to cure cancer, so why would anyone need Dara?
Markets are far from perfect... -
Sloan Kettering Institute identifies new way to combat a serious CAR-T cell therapy side effect!! Det bliver spændende at følge! https://www.mskcc.org/blog/study-identifies-new-way-combat-serious-car-cell-therapy-side-effect?sf191604095=1#utm_source=Twitter&utm_medium=Organic&utm_campaign=062218Cart&utm_content=Research
-
Denne presentation er vist ikke så gammel ? http://ir.genmab.com/static-files/883e0329-61cc-418c-8703-cf8cc8e010f1
-
Det er algoritmehandel i A/B - gruppen som kører det løb. Nettosalget ændrer sig ikke meget.
-
Utroligt så nemt det er, at flytte kursen den ene eller anden vej.
-
@Bulder...hvis vi lever så længe;)...On average, preclinical research takes five to seven years and costs several million dollars to complete, according to FasterCures (a nonprofit organization dedicated to increasing the speed of drug discovery across all therapeutic areas). Once this work is done, the drug developer can apply to the FDA for approval to start clinical trials by submitting an investigational new drug application (IND).
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind